AKT1 but not AKT2 single nucleotide polymorphisms are associated with the risk of microscopic polyangiitis

Lizhen Li1, Huifang Tan1, You Peng2

  • 1Department of Nephrology, Hunan Provincial People's Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, China.

Peerj
|February 23, 2026
PubMed
Abstract

Insights

Genetic analysis reveals AKT1 variants are associated with reduced risk of microscopic polyangiitis (MPA), a severe autoimmune vasculitis. AKT1, not AKT2, shows a significant link, suggesting a potential therapeutic target for MPA.

Area of Science:

  • Genetics
  • Immunology
  • Rheumatology

Background:

  • Microscopic polyangiitis (MPA) is a severe form of antineutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis, AAV).
  • MPA is strongly linked to myeloperoxidase/perinuclear anti-neutrophilic cytoplasmic antibodies (MPO/P-ANCA).
  • The genetic contribution of AKT signaling components, particularly AKT1 and AKT2, to MPA susceptibility is not well understood.

Purpose of the Study:

  • To investigate the association of single-nucleotide polymorphisms (SNPs) in AKT1 and AKT2 genes with microscopic polyangiitis (MPA).
  • To explore the potential role of AKT signaling pathways in MPA pathogenesis.
  • To identify specific genetic variants and haplotypes associated with MPA risk.

Main Methods:

  • A case-control study involving 202 MPA patients and 596 controls.
  • Genotyping of seven SNPs in AKT1 and AKT2.
  • Association analyses using multiple genetic models, gene-level, and set-based approaches.
  • Haplotype reconstruction, SNP-SNP interaction testing, and expression quantitative trait locus (eQTL) analysis.

Main Results:

  • Specific AKT1 variants (rs2498786 and rs1130233) were significantly associated with reduced MPA risk, especially in P-ANCA-positive patients.
  • Gene-level analysis showed a significant association for the AKT1 gene set (OR = 0.884, P = 0.002), but not for AKT2.
  • Protective AKT1 haplotypes and high-risk genotype combinations were identified.
  • eQTL analysis indicated that protective AKT1 alleles correlate with increased AKT1 expression in immune cells.

Conclusions:

  • AKT1 is implicated as a genetic factor contributing to MPA susceptibility.
  • The findings suggest AKT1 signaling may influence neutrophil function and vascular maintenance in MPA.
  • AKT2 does not appear to be associated with MPA risk, highlighting the specificity of AKT1's role.
  • AKT1 signaling represents a potential therapeutic target for MPA.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
20
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.9K